The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index; 84 of the 190 sources its claims cite were checked for support.
The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges
Open accessAbstract
The revival of psilocybin in psychopharmacological research heralds a potential paradigm shift for treating mood and anxiety disorders, and other psychiatric conditions beyond the psychotic spectrum. This critical review evaluates current evidence on psilocybin's efficacy, juxtaposing potential benefits with the practical aspects of psychedelic-Assisted psychotherapy (PAP) and the methodological constraints of existing research. An electronic literature search was conducted using PubMed/MEDLINE, selecting studies published up to December 2023 that explored the clinical use of psilocybin in mood and anxiety disorders, obsessive-compulsive disorder, post-traumatic stress disorder, and substance use disorder. Despite promising preliminary results suggesting psilocybin's efficacy in alleviating depression and anxiety, as well as obsessions, compulsions, and addictive behaviors, significant evidence gaps persist. These include evaluating the efficacy of psilocybin compared to standard antidepressants or anxiolytic molecules and identifying patient subpopulations that might benefit most from PAP. Concerns about psilocybin's safety, long-term efficacy, and optimal dosage remain unclear due to previous trials' limitations. Real-world implementation faces challenges, including infrastructural requirements, personnel training, and unresolved legal and ethical issues. This paper argues for further research to substantiate the evidence base, emphasizing the need for larger studies that overcome current methodological limitations and explore psilocybin's full therapeutic potential. While psilocybin holds promise for psychiatry, its successful translation from research to clinical practice demands more robust evidence on efficacy, safety, and methodological rigor. In addition, other factors, such as cultural stigma and legal/ethical issues, need to be successfully addressed to facilitate psilocybin's implementation in healthcare systems. © The Author(s), 2024. Published by Cambridge University Press.
Overview
CoChat Summary
## TL;DR
This critical review argues that psilocybin shows promising efficacy for depression and anxiety, but the evidence base is still limited by small, heterogeneous trials and major methodological gaps. The paper emphasizes that real-world use will require stronger randomized evidence, careful dosing and psychotherapy integration, and clear ethical/legal frameworks.
## Key findings
- Across the reviewed literature, psilocybin showed the most robust evidence for major depressive disorder (MDD), anxiety/depressive symptoms associated with life-threatening cancer, and treatment-resistant depression (TRD); in a recent meta-analysis, psilocybin at 1 mg to 25 mg produced significant reductions in depressive symptoms in patients not taking other psychotropic medications.
- In the 2021 RCT of 59 patients with MDD, there was no difference between psilocybin 25 mg and escitalopram by week 6 on QIDS-SR-16 (8.0 vs 6.0; p = 0.17).
- In a 2023 randomized, double-blind, placebo-controlled trial of 52 patients with MDD, psilocybin 0.215 mg/kg produced greater symptom reduction than placebo by day 14 on MADRS (15.0 to 1.3; Cohen’s d = 0.97; p = 0.0011).
- The paper reports a 2022 trial in 24 patients with MDD in which pretreatment psilocybin 20 and 30 mg/70 kg yielded an antidepressant response rate of 75% and remission of 58% by month 12; it also notes 33% of participants used other antidepressants during follow-up.
## Methods
- This is a critical review, not a systematic review; the authors state it was intended to provide an expert clinical opinion on psilocybin’s evidence, practical implementation, and future directions.
- They conducted an electronic literature search in PubMed/MEDLINE for English-language articles published from inception to December 2023, using psilocybin combined with terms related to depressive disorders, bipolar depression, anxiety disorders, OCD, PTSD, and SUD.
- The review synthesized RCTs, non-randomized studies, open-label trials, pilot studies, secondary follow-up analyses, and meta-analyses, with attention to safety, dosing, PAP, ethics, and legal issues.
## Limitations
- The paper states that the evidence comes from a mix of RCTs not always well-designed, non-randomized studies, open-label trials, and pilot studies, and that this prevents conclusive claims about antidepressant efficacy, especially long term.
- It explicitly notes small sample sizes, lack of diversity, selection bias, inconsistent correction for multiple testing, lack of randomization in some studies, short follow-up, and frequent reliance on open-label, crossover, single-dose, and waiting-list designs.
- The text also makes evident that conclusions are limited by the review’s non-systematic approach and by the fact that the authors rely heavily on previously published studies rather than new primary data.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
49 Valid · 4 Not valid · 60 Not checked · 43 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, it has also been reported after recreational psilocybin use, often together with alcohol and cannabis consumption. 15”
§ MNESYS -Mood and Psychosis Sub-Project (Spoke 5) [Collaborative Author Group]: Luigi Grassi (University of Ferrara, Ferrara, Italy); Alessio Maria Monteleone and Silvana Galderisi (University of Campania, Naples, Italy); Alessandro Bertolino (University of Bari, Bari, Italy); Mirella Ruggeri and Sarah Tosato (University of Verona, Verona, Italy); Valdo Ricca (University of Florence, Florence, Italy); Gianluca Serafini (University of Genoa, Genoa, Italy); Cinzia Niolu (Tor Vergata University of Rome, Rome, Italy); Pierluigi Politi (University of Pavia, Pavia, Italy). > Safety profile and addictive potential
What the sources say
- Partly supportedcites [15] 15. Dodd S, Norman TR, Eyre HA, et al. Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy. CNS Spectr. 2022; 1 -11. sourceExperimental — accuracy not yet measured
The Drug safety section reports HPPD in a recreational psilocybin user who also used alcohol and cannabis. It describes one case, so it does not support the claim that these substances are often used together in reported cases. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“for example, in medical and research settings there is no risk of withdrawal symptoms for psilocybin”
§ MNESYS -Mood and Psychosis Sub-Project (Spoke 5) [Collaborative Author Group]: Luigi Grassi (University of Ferrara, Ferrara, Italy); Alessio Maria Monteleone and Silvana Galderisi (University of Campania, Naples, Italy); Alessandro Bertolino (University of Bari, Bari, Italy); Mirella Ruggeri and Sarah Tosato (University of Verona, Verona, Italy); Valdo Ricca (University of Florence, Florence, Italy); Gianluca Serafini (University of Genoa, Genoa, Italy); Cinzia Niolu (Tor Vergata University of Rome, Rome, Italy); Pierluigi Politi (University of Pavia, Pavia, Italy). > Safety profile and addictive potential
What the sources say
- Partly supportedcites [8] 8. Scala M, Fanelli G, De Ronchi D, Serretti A, Fabbri C. Clinical specificity profile for novel rapid acting antidepressant drugs. Int Clin Psychopharmacol. 2023; 38 (5):297 -328. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) refers to a lack of psilocybin-induced withdrawal and rebound symptoms, supporting the claim in the studied settings. But the Conclusion (page unavailable) says withdrawal symptoms need longer follow-up to be reliably assessed, so the categorical assertion of no risk goes beyond the paper. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Electrophysiology studies also revealed that psilocybin reduces alpha, beta, and delta band activity in both healthy and depressed individuals”
§ MNESYS -Mood and Psychosis Sub-Project (Spoke 5) [Collaborative Author Group]: Luigi Grassi (University of Ferrara, Ferrara, Italy); Alessio Maria Monteleone and Silvana Galderisi (University of Campania, Naples, Italy); Alessandro Bertolino (University of Bari, Bari, Italy); Mirella Ruggeri and Sarah Tosato (University of Verona, Verona, Italy); Valdo Ricca (University of Florence, Florence, Italy); Gianluca Serafini (University of Genoa, Genoa, Italy); Cinzia Niolu (Tor Vergata University of Rome, Rome, Italy); Pierluigi Politi (University of Pavia, Pavia, Italy). > Introduction
What the sources say
- Partly supportedcites [27] 27. Le GH, Wong S, Badulescu S, et al. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: a systematic review. J Affect Disord. 2024; 355 :342 -354. sourceExperimental — accuracy not yet measured
The Imaging studies section (page unavailable) reports reduced cortical oscillatory power on MEG after psilocybin in 15 male participants. It does not identify reductions in the alpha, beta, and delta bands or report an electrophysiological finding in depressed individuals; the depression findings cited there come from fMRI. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [28] 28. Skosnik PD, Sloshower J, Safi-Aghdam H, et al. Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: relationship to symptoms. J Psychopharmacol (Oxf). 2023; 37 (7):687 -697. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“HPPD II, conversely, usually presents as recurrent, long-term, distressing, and pervasive perceptive disturbances.”
§ MNESYS -Mood and Psychosis Sub-Project (Spoke 5) [Collaborative Author Group]: Luigi Grassi (University of Ferrara, Ferrara, Italy); Alessio Maria Monteleone and Silvana Galderisi (University of Campania, Naples, Italy); Alessandro Bertolino (University of Bari, Bari, Italy); Mirella Ruggeri and Sarah Tosato (University of Verona, Verona, Italy); Valdo Ricca (University of Florence, Florence, Italy); Gianluca Serafini (University of Genoa, Genoa, Italy); Cinzia Niolu (Tor Vergata University of Rome, Rome, Italy); Pierluigi Politi (University of Pavia, Pavia, Italy). > Safety profile and addictive potential
What the sources say
- Supportedcites [40] 40. Martinotti G, Santacroce R, Pettorruso M, et al. Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. Brain Sci. 2018; 8 (3):47. source
The Introduction describes HPPD II as having a long-term, pervasive course, severe impairment, and long-lasting recurrent episodes, in contrast to the usually less distressing HPPD I. The Clinical Features section adds that perceptual distortions recur more frequently after HPPD II onset. The supplied passages do not give page numbers. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the persistence of some residual symptoms (e.g., cognitive and sleep disturbances)”
§ MNESYS -Mood and Psychosis Sub-Project (Spoke 5) [Collaborative Author Group]: Luigi Grassi (University of Ferrara, Ferrara, Italy); Alessio Maria Monteleone and Silvana Galderisi (University of Campania, Naples, Italy); Alessandro Bertolino (University of Bari, Bari, Italy); Mirella Ruggeri and Sarah Tosato (University of Verona, Verona, Italy); Valdo Ricca (University of Florence, Florence, Italy); Gianluca Serafini (University of Genoa, Genoa, Italy); Cinzia Niolu (Tor Vergata University of Rome, Rome, Italy); Pierluigi Politi (University of Pavia, Pavia, Italy). > Introduction
What the sources say
- Not checked — no full text of the sourcecites [4] 4. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009; 29 (3): 259 -266. source
- Not checked — no full text of the sourcecites [5] 5. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010; 71 (10):1259 -1272. source
- Partly supportedcites [6] 6. Conradi HJ, Ormel J, De Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med. 2011; 41 (6):1165 -1174. sourceExperimental — accuracy not yet measured
The Results (p. 2) report that cognitive problems and sleeping problems persisted during periods of remission, supporting the wording of the printed citing sentence. The Introduction (p. 2) says incomplete remission after psychological and pharmacological treatment is common, but the study does not establish that standard antidepressants specifically leave those symptoms. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [7] 7. Sforzini L, Worrell C, Kose M, et al. A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Mol Psychiatry. 2022; 27 (3):1286 -1299.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
95 more claims · 24 with their cited sources checked
Create a free account to see all 156 claims and every source verdict.
- Probably not a substantial claim. 19
- It may state two separate claims as one. 41
- The quote only partly states this claim. 1
Citations
Cites
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Roberts, B. W., Walton, K. E., & Viechtbauer, W. (2006) · Psychological Bulletin · doi:10.1037/0033-2909.132.1.1 · Cited by 3,318 · cited 1×
“65 According to the above, we glimpse the potential benefits of using the PAP paradigm in personality disorders, especially considering that to date no drugs are specifically approved to treat these conditions.”
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 2×
“32 The exclusion of patients with psychotic symptoms and/or suicidal ideation aims to avoid the rare possibility of inducing psychotomimetic adverse events and suicidal behavior in patients with congruent ideation.”
InfluentialBoyer, E. W., & Shannon, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041867 · Cited by 1,821
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 2×
“16 More recently, these effects were found to be closely dependent on plasma psilocin levels (i.e., psilocybin ’ s active metabolite) and serotonin 5HT 2A receptor occupancy rates, 17 which increases glutamate tone, thus leading to more active synaptic plasticity.”
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 2×
“, 60, 73-77 73-77 Open-label studies 25,39,57,78-81 and two follow-up analyses 61, 62 supported the overall positive findings RCTs.”
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391 · cited 5×
“26 In terms of safety, psilocybin was better tolerated than escitalopram, 26 although the latter contributed to mitigating psilocybin-induced acute autonomic adverse events in the study arm evaluating the response to psilocybin after pretreatment with escitalopram.”
InfluentialEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Research works printed but not linked: 2
- 10.1136/bmj.p1599;2023 · doi:10.1136/bmj.p1599;2023
- 107. Bender, L , Cobrinik, L , Faretra, G. Biological Treatment of Mental Illness: Proceedings of the II International Conference of the Manfred Sakel Foundation;1963.
Cited by
Latif, R., & Nawaz, T. (2025) · Phytochemistry Reviews · doi:10.1007/s11101-025-10194-7 · Cited by 164
Anhedonia: Current and future treatments
Serretti, A. (2025) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.70088 · Cited by 39
“100,101 Likewise, novel pharmacological approaches, such as combining dextromethorphan ‐ bupropion (AXS ‐ 05) or adjunctive brexpiprazole, highlight the potential synergy between multiple receptor targets and pathways.”
Self-citationEthical issues with psychedelic-assisted treatments in psychiatry: A systematic scoping review
Caporuscio, C., Poppe, C. J., Gieselmann, A., & Repantis, D. (2025) · Psychological Medicine · doi:10.1017/s0033291725101761 · Cited by 18
“…seem to be extremely low, especially for classic psy-chedelics like LSD or psilocybin (Johnson et al., 2008; Schlag et al., 2022), there are cases of psychedelics triggering hallucinogen persisting perception disorder or psychosis in predisposed subjects (Scala et al., 2024; Schlag et al., 2022).”
Multisensory integration, brain plasticity and optogenetics in visual rehabilitation
Lucchesi, M., Maya‐Vetencourt, J. F., & Rusciano, D. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1590305 · Cited by 17
Exploring psilocybin’s role in mental health and palliative medicine: a path to improved well-being
Umbacia, M. A., León, M., Quintero, J.-M., Castro, L.-M., Páez, V., Dodd, S., & Bustos, R. (2025) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2025.2488786
“[76] Unfortunately, there is a paucity of long term follow up data from people treated with psilocybin [25].”
Metadata
- Authors
- Scala, M., Fabbri, C., Fusar-Poli, P., Di Lorenzo, G., Ferrara, M., Amerio, A., Fusar-Poli, L., Pichiecchio, A., Asteggiano, C., Menchetti, M., De Ronchi, D., MNESYS - Mood and Psychosis Sub-Project (Spoke 5), Fanelli, G., & Serretti, A.
- Affiliations
- Research Institute Hospital 12 de Octubre (ES)
- University of Bologna (IT)
- University of Ferrara (IT)
- University of Pavia (IT)
- Fondazione Istituto Neurologico Nazionale Casimiro Mondino (IT)
- Radboud University Medical Center (NL)
- Università degli Studi di Enna Kore (IT)
- Corresponding author
- Fanelli, Giuseppe
- ORCID
- Venue
- CNS Spectrums
- Publisher
- Cambridge University Press (CUP)
- Published
- 2024-12
- Volume
- 29
- Issue
- 6
- Pages
- 570-584
- ISSN
- 1092-8529 (ISSN-L)
- 2165-6509
- OpenAlex
- W4405207112
- Cited by
- 13
- References
- 114
- Citations by year
- 2026: 5 · 2025: 8
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- CNS Spectrums (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psilocybin, psychedelic-assisted psychotherapy, mood disorders, anxiety disorders, depression, obsessive-compulsive disorder, post-traumatic stress disorder, substance use disorders, dose optimization, translation to clinical practice, legal and ethical issues, cultural stigma
- MeSH terms
- Anxiety Disorders, Hallucinogens, Humans, Psilocybin, Psychotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges. https://app.cochat.ai/papers/10.1017/s1092852924002268
- The paper
- Scala, M., Fabbri, C., Fusar-Poli, P., Di Lorenzo, G., Ferrara, M., Amerio, A., Fusar-Poli, L., Pichiecchio, A., Asteggiano, C., Menchetti, M., De Ronchi, D., MNESYS - Mood and Psychosis Sub-Project (Spoke 5), Fanelli, G., & Serretti, A. (2024). The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges. CNS Spectrums. https://doi.org/10.1017/s1092852924002268
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.